Epizyme Inc. (EPZM) had a good day on the market for Friday December 06 as shares jumped 19.09% to close at $18.22. About 2.44 million shares traded hands on 17,555 trades for the day, compared with an average daily volume of n/a shares out of a total float of 91.07 million. After opening the trading day at $16.41, shares of Epizyme Inc. stayed within a range of $18.40 to $16.30.
With today’s gains, Epizyme Inc. now has a market cap of $1.66 billion. Shares of Epizyme Inc. have been trading within a range of $17.00 and $5.14 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing & commercializing novel epigenetic medicines. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL), Phase II clinical trial for relapsed or refractory patients with mesothelioma, Phase I dose-escalation and expansion study for children with INI1-negative solid tumors. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias & PRMT5 inhibitor.
Epizyme Inc. is based out of Cambridge, MA and has some 124 employees. Its CEO is Robert B. Bazemore.
